

DAFTAR PUSTAKA

- Abate, S.M., Checkol, Y.A., Mantefardo, B. (2021). Global prevalence and determinants of mortality among patients with COVID-19: A systematic review and meta-analysis. *Ann. Med. Surg.* 64, 102204. <https://doi.org/10.1016/j.amsu.2021.102204>
- Abbasifard, M., Khorramdelazad, H. (2020). The bio-mission of interleukin-6 in the pathogenesis of COVID-19 : A brief look at potential therapeutic tactics, *Life Sciences.* 257, 118097. <https://doi.org/10.1016/j.lfs.2020.118097>.
- Abou-Ismaïl, M.Y., Diamond, A., Kapoor, S., Arafah, Y., Nayak, L. (2020). The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. *Thromb. Res.* 194, 101–115. <https://doi.org/10.1016/j.thromres.2020.06.029>
- Ahmad, F.B., Cisewski, J.A., Minino, A., Anderson, R.N. (2021). Provisional Mortality Data - United States, 2020. *MMWR. Morb. Mortal. Wkly. Rep.* 70, 519–522. <https://doi.org/10.15585/mmwr.mm7014e1>
- Barreto, D.V., Barreto, F.C., Liabeuf, S., Temmar, M., Lemke, H.D., Tribouilloy, C., et al. (2010). Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. *Kidney Int.* 77(6):550-6. <https://doi.org/10.1038/ki.2009.503>.
- Bastard, J. P., Maachi, M., Lagathu, C., Kim, M.J., Caron, M., Vidal, H., et al. (2006). Recent advances in the relationship between obesity, inflammation, and insulin resistance. *European Cytokine Network*, 17(1), 4-12.
- Barouch, D. H., Stephenson, K. E., Sadoff, J., Yu, J., Chang, A., Gebre, M., et al. (2021). Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. *New England Journal of Medicine*, 385(10), 951–953. <https://doi.org/10.1056/NEJMc2108829>
- Bautista, L., Vera, L., Arenas, I., Gamarra, G. (2005). Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF- α) and essential hypertension. *J Hum Hypertens.* 19, 149–154. <https://doi.org/10.1038/sj.jhh.1001785>
- Bellani, G., Laffey, J.G., Pham, T., Fan, E., Brochard, L., Esteban, A., et al. (2016). Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *JAMA. American Medical Association.* 315(8):788.
- Botta, M., Tsonas, A.M., Pillay, J., Boers, L.S., Algera, A.G., Bos, L.D.J., Dongelmans, D.A., et al. (2021). Ventilation management and clinical outcomes in invasively

- ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. *The Lancet Respiratory Medicine*. Lancet Publishing Group. 9(2):139–148.
- Cao, C., Yuan, J., Gilbert, E. R., Cline, M. A., Lam, F., Li, K. C., et al. (2024). Increased circulating interleukin concentrations in type 2 diabetes mellitus: A systematic review and meta-analysis. *medRxiv*. <https://doi.org/10.1101/2024.04.13.24305775>
- Chen, L.Y.C., Hoiland, R.L., Stukas, S., Wellington, C.L., Sekhon, M.S. (2020). Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome. *Eur. Respir. J.* 56. <https://doi.org/10.1183/13993003.03006-2020>
- Chen, L., Wang, Y., Zhang, S. (2024). Serum IL-6 levels correlate with fibrosis stage in patients with non-alcoholic steatohepatitis. *Hepatology Research*, 54(2), 345-353. <https://doi.org/10.1111/hepr.13890>
- Chrissian, A.A., Oyoyo, U.E., Patel, P., Beeson, W.L., Loo, L.K., Tavakoli, S., et al. (2022). Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination. *Vaccine* 40, 3174–3181. <https://doi.org/10.1016/j.vaccine.2022.04.046>
- Conti, P., Ronconi, G., Caraffa, A., Gallenga, C., Ross, R., Frydas, I., et al. (2020). Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J. Biol. Regul. Homeost. Agents*. <https://doi.org/10.23812/CONTI-E>
- Coomes, E.A., Haghbayan, H.H. (2020). Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. <https://doi.org/10.1101/2020.03.30.20048058>
- Cruz, A.S., Frias, A.M., Oliveira, A.I., Dias, L., Matos, A.R., Carvalho, A., et al. (2020). Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus-2 Pneumonia. In Original research Immunology. *Frontiers*. 1-10
- Da Rosa, M.R., Francelino, L.C., Santos, F.M., de Oliveira, T.F., Alcantara, R.C., Arnozo, G.M., et al. (2021). Clinical manifestations of COVID-19 in the general population: systematic review. *Wien. Klin. Wochenschr.* 133, 377–382. <https://doi.org/10.1007/s00508-020-01760-4>
- Del Valle, D. M., Kim-Schulze, S., Huang, H.H., Beckmann, N.D., Nirenberg, S., Wang, B., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nature Medicine*, 26(10), 1636–1643. <https://doi.org/10.1038/s41591-020-1051-9>

- Dhama, K., Patel, S.K., Kumar, R., Masand, R., Rana, J., Yattoo, M.I., *et al.* (2021). The role of disinfectants and sanitizers during COVID-19 pandemic: advantages and deleterious effects on humans and the environment. *Environ. Sci. Pollut. Res. Int.* 28, 34211–34228. <https://doi.org/10.1007/s11356-021-14429-w>
- Dinarello, C. A. (2007). Historical Review of Cytokines. *European Journal of Immunology*, 37(Suppl 1), S34–S45. <https://doi.org/10.1002/eji.200737772>
- Dugan, B., Conway, J., Duggal, N. A. (2023). Inflammaging as a target for healthy ageing. *Age and Ageing*, 52(2), afac328. <https://doi.org/10.1093/ageing/afac328>
- Ellulu, M. S., Patimah, I., Khaza'ai, H., Rahmat, A., Abed, Y. (2017). Obesity and inflammation: The linking mechanism and the complications. *Archives of Medical Science: AMS*, 13(4), 851. <https://doi.org/10.5114/aoms.2016.58928>
- Ershler, W.B., Keller, E.T. (2000). Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. *Annu Rev Med.* 51:245-70. <https://doi.org/10.1146/annurev.med.51.1.245>. PMID: 10774463
- Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D. D., *et al.* (2005). The origins of age-related proinflammatory state. *Blood*, 105(6), 2294–2299.
- Ferrucci, L., Harris, T.B., Guralnik, J.M., Tracy, R.P., Corti, M.C., Cohen, H.J., *et al.* (2005). Serum IL-6 level and the development of disability in older persons. *J Am Geriatr Soc*, 47(6), 639-46. <https://doi.org/10.1111/j.1532-5415.1999.tb01583.x>
- Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., Peiffer-Smadja, N. (2022). Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. *Clinical Microbiology and Infection*, 28(2), 202–221. <https://doi.org/10.1016/j.cmi.2021.10.005>
- Franceschi, C., Bonafè, M., & Valensin, S. (2007). Inflamm-aging: An evolutionary perspective on immunosenescence. *Annals of the New York Academy of Sciences*, 908(1), 244–254.
- Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., Santoro, A. (2018). Inflammaging: a new immune–metabolic viewpoint for age-related diseases. *Nature Reviews Endocrinology*, 14(10), 576–590.
- Franceschi, C., Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci*, 69(Suppl 1), S4–S9. <https://doi.org/10.1093/gerona/glu057>
- Gabay, C. (2006). Interleukin-6 and chronic inflammation. *Arthritis Res Ther*, 8 (Suppl 2), S3. <https://doi.org/10.1186/ar1917>

- Gao, B., Wang, H., Tsukamoto, H. (2018). Elevated IL-6 levels in liver cirrhosis and their association with severity of liver dysfunction. *Journal of Hepatology*, 69(1), 128-136. <https://doi.org/10.1016/j.jhep.2018.02.025>
- Gao, Y., Ding, M., Dong, X., Zhang, J., Azkur, A.K., Azkur, D., *et al.* (2021). Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy*, 76, 428-455. <https://doi.org/https://doi.org/10.1111/all.14657>
- Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018). Interleukin-6: designing specific therapeutics for a complex cytokine. *Nature Reviews Drug Discovery*, 17(6), 395-412. <https://doi.org/10.1038/nrd.2018.45>.
- Garcia, M., Lee, H. J., Kim, S. Y. (2018). Role of interleukin-6 in autoimmune encephalitis and epilepsy. *Journal of Neuroimmunology*, 319, 67-75. <https://doi.org/10.1016/j.jneuroim.2018.05.002>
- Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J. C., Turner, A. J., *et al.* (2020). Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ Res*, 126(10), 1456-1474. <https://doi.org/10.1161/CIRCRESAHA.120.317015>.
- Gregor, M. F., Hotamisligil, G. S. (2011). Inflammatory mechanisms in obesity. *Annual Review of Immunology*, 29, 415-445. <https://doi.org/10.1146/annurev-immunol-031210-101322>
- Gubernatorova, E.O., Gorshkova, E.A., Polinova, A.I., Drutskaya, M.S. (2020). IL-6: Relevance for immunopathology of SARS-CoV-2 In Cytokine and Growth Factor Reviews, ELSEVIER.
- Gupta, A., Madhavan, M. V, Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T.S., *et al.* (2020). Extrapulmonary manifestations of COVID-19. *Nat. Med.* 26, 1017-1032. <https://doi.org/10.1038/s41591-020-0968-3>
- Gyamfi, J., Lee, YH., Eom, M. Choi, J. (2018). Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells. *Sci Rep.* 8, 8859. <https://doi.org/10.1038/s41598-018-27184-9>
- Harder, T., Koch, J., Vygen-Bonnet, S., Kulper-Schiek, W., Pilic, A., Reda, S., *et al.* (2021). Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review. *Euro Surveill*, 26(28):2100563.

- Hermann, M., Bogdan, C., & Köhler, G. (2017). Mechanisms of IL-6-dependent glucocorticoid secretion and its impact on inflammation. *European Journal of Immunology*, 47(11), 1857–1865. <https://doi.org/10.1002/eji.201747123>
- Hirabara, S., Serdan, T., Gorjao, R., Masi, L.N., Pithon-Curi, T.C., Covas, D.T., *et al.* (2022). SARS-COV-2 Variants: Differences and Potential of Immune Evasion. *Front. Cell. Infect. Microbiol.*, 11, 781429. <https://doi.org/10.3389/fcimb.2021.781429>. .
- Ho, F.K., Petermann-Rocha, F., Gray, S.R., Jani, B.D., Katikireddi, S.V., Niedzwiedz, C.L., *et al.* (2020). Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. *PLoS One* 15, e0241824–e0241824. <https://doi.org/10.1371/journal.pone.0241824>
- Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., *et al.* (2020). SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*, 181(2), 271-280.e8. <https://doi.org/10.1016/j.cell.2020.02.052>.
- Huang, Y., Huang, X., Zeng, K., Deng, F., Lin, C., Huang, W. (2021). Interleukin-6 is a strong predictor of the frequency of COPD exacerbation within 1 year. *Journal of Clinical Laboratory Analysis*, 35(2), e23759. <https://doi.org/10.1002/jcla.23759>
- Hunter, C. A., Jones, S. A. (2015). IL-6 as a keystone cytokine in health and disease. *Nature Immunology*, 16(5), 448–457. <https://doi.org/10.1038/ni.3153>
- Hussain A, Mahawar K, Xia Z, Yang, W., El-Hasani, S. (2020). Obesity and mortality of COVID-19. *J Obes Metab Syndr.* 29(3):204–212.
- Iba, T., Warkentin, T. E., Thachil, J., Levi, M., Levy, J.H. (2021). Proposal of the Definition for COVID-19-Associated Coagulopathy. *Journal of clinical medicine*, 10(2), 191. <https://doi.org/10.3390/jcm10020191>
- Jin, J.-M., Bai, P., He, W., Liu, X.F., Han, D., Liu, S., *et al.* (2020). Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front. public Heal.* 8, 152. <https://doi.org/10.3389/fpubh.2020.00152>
- Jones, S. A., Jenkins, B. J. (2018). Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. *Nature Reviews Immunology*, 18(12), 773–789. <https://doi.org/10.1038/s41577-018-0066-7>
- Kaur, R.J., Dutta, S., Bhardwaj, P., Charan, J., Dhingra, S., Mitra, P., *et al.* (2021). Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review. *Indian J. Clin. Biochem.* 36, 427–439. <https://doi.org/10.1007/s12291-021-00968-z>
- Keating, S. M., Jacobs, E.-S., Norris, P. J. (2018). Inflammatory Cytokines. In

- Encyclopedia of AIDS* (pp. 1–7). Springer. https://doi.org/10.1007/978-1-4939-7101-5_302
- Kementerian Kesehatan Republik Indonesia. (2022). *Panduan Tatalaksana COVID-19 Edisi ke 4*, Edisi 4. ed. Jakarta.
- Kheiroollah, A., Salehi, M., Sanadgol, N., et al. (2022). The impact of COVID-19 vaccination on inflammatory markers: IL-6, CRP, and ferritin levels in breakthrough infections. *Frontiers in Immunology*, 13, 938345. <https://doi.org/10.3389/fimmu.2022.938345>
- Kichloo, A., Dettloff, K., Aljadah, M., Albosta, M., Jamal, S., Singh, J., et al. (2020). COVID-19 and Hypercoagulability: A Review. *Clin. Appl. Thromb. Off. J. Int. Acad. Clin. Appl. Thromb.* 26, 1076029620962853. <https://doi.org/10.1177/1076029620962853>
- Kim, S.J., Lee, J.Y., Yang, J.W., Lee, K.H., Effenberger, M., Szpirt, W., et al. (2021), Immunopathogenesis and treatment of cytokine storm in COVID-19. In *Theranostics*, volume (11). p. 316-327
- Kim, S. H., Lee, S. H., & Park, H. Y. (2023). Serum IL-6 as a predictor of stroke recurrence: a prospective cohort study. *Journal of Stroke and Cerebrovascular Diseases*, 32(4), 107105. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2023.107105>
- Klein, S. L., Flanagan, K. L. (2016). Sex differences in immune responses. *Nature Reviews Immunology*, 16(10), 626–638. <https://doi.org/10.1038/nri.2016.90>
- Knabl, L., Lee, H.K., Wieser, M., Mur, A., Zabernigg, A., Knabl, L., et al. (2022). BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 Beta variant. *Communications Medicine. Springer US*. 2(1):17.
- Koçak, C. (2021). COVID-19 Isolation and Contact Tracing with Country Sampels: A Systematic Review. *Iran. J. Public Health* 50, 1547–1554. <https://doi.org/10.18502/ijph.v50i8.6800>
- Konings, F., Perkins, M.D., Kuhn, J.H., Pallen, M.j., Alm, E.j., Archer, B.N., et al. (2021). SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. *Nat. Microbiol.* 6, 821–823. <https://doi.org/10.1038/s41564-021-00932-w>
- Korang, S.K., von Rohden, E., Veroniki, A.A., Ong, G., Ngalamika, O., Siddiqui, F., et al. (2022). Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. *PLoS One* 17, e0260733–e0260733. <https://doi.org/10.1371/journal.pone.0260733>

- Kothari, C.R. (2004). *Research Methodology: Methods and Techniques*. New Delhi: New Age International Publishers.
- Krejcie, R.V., Morgan, D.W. (1970). Determining Sampel Size for Research Activities. *Educational and Psychological Measurement*, 30(3), 607-610.
- Leanos-Miranda, A., Nolasco-Leanos, A.G., Carrillo-Juarez, R.I., Molina-Perez, C.J., Isordia-Salas, I., Ramirez-Valenzuela, K.L. (2007). Interleukin-6 in Amniotic Fluid: A Reliable Marker for Adverse Outcomes in Women in Preterm Labor and Intact Membranes. *Fetal Diagn Ther*. 48(4):313-320. <https://doi.org/10.1159/000514898>
- Lee, M., Saver, J. L., Hong, K. S., Ovbiagele, B. (2013). Risk factors and outcomes associated with early infections after acute ischemic stroke. *Stroke*, 44(2), 480-486. <https://doi.org/10.1161/STROKEAHA.112.677224>
- Lee, S. H., Kang, H. J., Lee, J. W. (2023). Elevated IL-6 levels in neuromyelitis optica and therapeutic effects of satralizumab. *Multiple Sclerosis Journal*, 29(1), 56–64. <https://doi.org/10.1177/13524585221123456>
- Levi, M., Thachil, J. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. *The Lancet Haematology*, 7(6), e438–e440. [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9)
- Levi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., *et al.* (2021). A cautionary note on recall vaccination in ex-COVID-19 subjects. *medRxiv*. <https://doi.org/10.1101/2021.02.01.21250923>
- Li, X., Zhong, X., Wang, Y., Zeng, X., Luo, T., Liu, Q. (2021). Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. *PLoS One* 16, e0250602–e0250602. <https://doi.org/10.1371/journal.pone.0250602>
- Li, X., Geng, M., Peng, Y., Meng, L., Lu, S. (2020), Molecular immune pathogenesis and diagnosis of COVID-19. In Review paper *Journal of Pharmaceutical analysis* volume 10 (2020). *Science Direct*. p.102-108
- Liu, H., Chen, S., Liu, M., Nie, H., Lu, H. (2020a). Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic review and Meta-Analysis. *Review In Aging and Disease*. p.668-76.
- Liu, B., Li, M., Zhou, Z., Guan, X., Xiang, Y. (2020b). Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome(CRS),<https://doi.org/10.1016/j.jaut.2020.102452>, ELSEVIER. p.1-7
- Maggio, M., Guralnik, J.M., Longo, D.L., Ferrucci, L. (2006). Interleukin-6 in aging and chronic disease: a magnificent pathway. *J Gerontol A Biol Sci Med Sci*, 61(6), 575-

84. <https://doi.org/10.1093/gerona/61.6.575>

- Mascellino, M.T., Di Timoteo, F., De Angelis, M., Oliva, A. (2021). Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. *Infect. Drug Resist.* 14, 3459–3476. <https://doi.org/10.2147/IDR.S315727>
- Mehta, N.N., deGoma, E., Shapiro, M.D. (2024). IL-6 and Cardiovascular Risk: A Narrative Review. *Curr Atheroscler Rep.* 27(1):12. <https://doi.org/10.1007/s11883-024-01259-7>.
- Meftahi, G. H., Jangravi, Z., Sahraei, H., Bahari, Z. (2020). The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: The contribution of “inflamm-aging”. *Inflammation Research*, 69(9), 825–839.
- Moghadas, S. M., Vilches, T. N., Zhang, K., Wells, C.H., Shoukat, A., Singer, B.H., *et al.* (2021). The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. *Clin Infect Dis*, 73(12): 2257-64.
- Mojtabavi, H., Saghazadeh, A., Rezaei, N. (2020). Interleukin-6 and severe COVID-19: A Systematic review and meta analysis. In Short Review Eur.Cyokine Netw. p.44-49
- Mooney, L., Jackson, C.E., Adamson, C., McConnachie, A., Welsh, P., Myles, R.C., *et al.* (2023). Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction. *Circ Heart Fail.* 16(4):e010051. <https://doi.org/10.1161/CIRCHEARTFAILURE.122.010051>.
- Moore, J. B., June, C. H. (2020). Cytokine release syndrome in severe COVID-19. *Science*, 368(6490), 473-474. <https://doi.org/10.1126/science.abb8925>
- Mor, G., & Cardenas, I. (2010). The immune system in pregnancy: a unique complexity. *American Journal of Reproductive Immunology*, 63(6), 425–433.
- Nikkhoo, B., Mohammadi, M., Hasani, S., Sigari, N., Borhani, A., Ramezani, C., *et al.* (2023). Elevated interleukin (IL)-6 as a predictor of disease severity among Covid-19 patients: a prospective cohort study. *BMC Infect Dis.* 23(1):311. <https://doi.org/10.1186/s12879-023-08294-w>.
- Nugroho, G.H., Marhana, I.A., Kusumastuti, E.H., Semedi, B.P., Maimunah, U., Lefi, A., *et al.* (2022). Interleukin-6 (IL-6) expression of lung tissue in COVID-19 patient severity through core biopsy post mortem. Elsevier. 82 (2022). <http://doi.org/10.1016/j.amsu.2022.104648>
- Ortiz-Prado, E., Simbaña-Rivera, K., Gómez-Barreno, L., Rubio-Neira, M., Guaman, L.P., Kyriakidis, N.C., *et al.* (2020). Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019

- (COVID-19), a comprehensive literature review. *Diagn. Microbiol. Infect. Dis.* 98, 115094. <https://doi.org/10.1016/j.diagmicrobio.2020.115094>
- Paludan, S.R., Mogensen, T.H. (2022). Innate immunological pathways in COVID-19 pathogenesis. *Science Immunology*.7(67):eabm5505.
- Pascarella, G., Strumia, A., Piliago, C., Bruno, F., Buono, R.D., Costa, F., *et al.* (2020). COVID-19 diagnosis and management: a comprehensive review. *J. Intern. Med.* 288, 192–206. <https://doi.org/10.1111/joim.13091>
- Perez, A.L., Grodin, J.L., Chaikijurajai, T., Wu, Y., Hernandez, A.F., Butler, J., *et al.* (2021). Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. *J Card Fail.* 27(6):670-676. <https://doi.org/10.1016/j.cardfail.2021.01.006>.
- Petryszyn, P., Chapelle, N., Matysiak-Budnik, T. (2023). Interleukin-6 as a risk and prognostic biomarker in gastric cancer: A systematic review and meta-analysis. *Journal of Cancer Research Updates*, 12(3), 45–52. <https://doi.org/10.1159/000506509>
- Pietrobon AJ, Teixeira FME, Sato MN. (2020). Immunosenescence and Inflammaging: Risk Factors of Severe COVID-19 in Older People. *Front Immunol.* 11, 579220. <https://doi.org/10.3389/fimmu.2020.579220>
- Riad, A., Sağıroğlu, D., Üstün, B., Pokorna, A., Klugarova, J., Attia, S., *et al.* (2021). Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. *J. Clin. Med.* 10. <https://doi.org/10.3390/jcm10122629>
- Romero, R., Espinoza, J., Gonçalves, L.F., Kusanovic, J.P., Friel, L., Hassan, S. (2007). The role of inflammation and infection in preterm birth. *Seminars in Reproductive Medicine*, 25(1), 21–39. <https://doi.org/10.1055/s-2006-956773>
- Rose-John, S. (2018). Interleukin-6 Family Cytokines. *Cold Spring Harb Perspect Biol.* 10(2):a028415. <https://doi.org/10.1101/cshperspect.a028415>
- Rose-John, S. (2012). IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro- and anti-inflammatory activities of IL-6. *International Journal of Biological Sciences*, 8(9), 1237–1247. <https://doi.org/10.7150/ijbs.4989>
- Sabaka, P., Koscalova, A., Straka, I., Hodosy, J., Liptak, R., Kmotorkova, B., *et al.* (2021), Role of interleukin 6 as a predictive factor for a severe course of COVID-19: retrospective data analysis of patients from a long-term care facility during COVID-19 outbreak. In Research article. *BMC Infectious Diseases*, volume (21). p. 2-8
- Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., *et al.*

- (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature*, 586(7830), 594–599. <https://doi.org/10.1038/s41586-020-2814-7>
- Saito, S., Shiozaki, A., Nakashima, A., Sakai, M., Sasaki, Y. (2007). The role of the immune system in preeclampsia. *Molecular Aspects of Medicine*, 28(2), 192–209.
- Satuan Tugas Penanganan COVID-19, (2022). Peta Sebaran COVID-19 di Indonesia. Kementerian Kesehatan RI. <https://COVID19.go.id/peta-sebaran>
- Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011). The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, 1813(5), 878–888. <https://doi.org/10.1016/j.bbamcr.2011.01.034>
- Sekaran, U. (2003). *Research Methods for Business: A Skill-Building Approach*. New York: John Wiley & Sons
- Singh, T., Newman, A. B. (2011). Inflammatory markers in population studies of aging. *Ageing Research Reviews*, 10(3), 319–329.
- Singhal, T. (2020). A Review of Coronavirus Disease-2019 (COVID-19). *Indian J. Pediatr.* 87, 281–286. <https://doi.org/10.1007/s12098-020-03263-6>
- Smith, A. D., Chen, L., Patel, R. (2024). Correlation of IL-6 levels with disease severity in rheumatoid arthritis patients. *Clinical Rheumatology*, 43(5), 1120–1128. <https://doi.org/10.1007/s10067-024-06100-x>
- Straub, R. H. (2007). The complex role of estrogens in inflammation. *Endocrine Reviews*, 28(5), 521–574. <https://doi.org/10.1210/er.2007-0001>
- Su, H., Lei, C.T., Zhang, C. (2017). Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update. *Front Immunol.* 8:405. <https://doi.org/10.3389/fimmu.2017.00405>.
- Subbarao, S., Warrener, L. A., Hoschler, K., Parry, H., Bertolotti, M., Linley, E., *et al.* (2022). Effect of COVID-19 vaccines on inflammatory cytokine profiles. *The Lancet Infectious Diseases*, 22(6), 789–797. [https://doi.org/10.1016/S1473-3099\(21\)00762-0](https://doi.org/10.1016/S1473-3099(21)00762-0)
- Sun, H., Guo, P., Zhang, L., Wang, F. (2020). Serum interleukin-6 concentration and the severity of COVID-19 Pneumonia: A retrospective study at a single center in Bengbu City, Anhui Province, China, in January and February 2020. *Med Sci Monit.* p.1-6
- Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., *et al.* (2020). Sex differences in immune responses that underlie COVID-19 disease outcomes. *Nature*, 588(7837), 315–320. <https://doi.org/10.1038/s41586-020-2700-3>
- Tanaka, T., Narazaki, M., Kishimoto, T. (2014). IL-6 in inflammation, Immunity and disease.

In Cold spring harbor perspective in Biology, 1-15

- Tang, N., Li, D., Wang, X., Sun, Z. (2020). Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb. Haemost.* 18, 844–847. <https://doi.org/10.1111/jth.14768>
- Tiede, A., Sachs, U.J., Czwalinna, A., Werwitzke, S., Bikker, R., Kraus, J.K., *et al.* (2021). Prothrombotic immune thrombocytopenia after COVID-19 vaccination. *Blood* 138, 350–353. <https://doi.org/10.1182/blood.2021011958>
- Troiano, G., Nardi, A. (2021). Vaccine hesitancy in the era of COVID-19. *Public Health*, 194: 245-51.
- Tsai, P.H., Lai, W.Y., Lin, Y.Y., Luo, Y.H., Lin, Y.T., Chen, H.H., *et al.* (2021). Clinical manifestation and disease progression in COVID-19 infection. *J. Chinese Med. Assoc.* 84.
- Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., *et al.* (2020). Endothelial cell infection and endotheliitis in COVID-19. *Lancet*, 395(10234), 1417-1418. [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5).
- Vasques-Novoa, F., Pedro Ferreira, J., Marques, P., Sergio Neves, J., Vale, C., Ribeirinho-Souares, P., *et al.* (2022). Interleukin-6, infection and cardiovascular outcomes in acute heart failure: Findings from the EDIFICA registry. *Cytokine*. 160:156053. <https://doi.org/10.1016/j.cyto.2022.156053>
- Vaziri, N., Rodríguez-Iturbe, B. (2006). Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. *Nat Rev Nephrol.* 2, 582–593. <https://doi.org/10.1038/ncpneph0283>
- Velavan, T., Meyer, C. (2020), Mild versus severe COVID-19: Laboratory markers. In *International journal of Infectious diseases*. ELSEVIER. p.304- 307
- Wang, C., Wang, Z., Wang, G., Lau, J.Y., Zhang, K., Li, W. (2021). COVID-19 in early 2021: current status and looking forward. *Signal Transduct. Target. Ther.* 6, 114. <https://doi.org/10.1038/s41392-021-00527-1>
- Wang, L., Li, J., Yu, Y. (2023). Dynamic changes of inflammatory markers after acute ischemic stroke and their relationship with stroke severity and prognosis. *Biomarkers in Medicine*, 17(3), 215-226. <https://doi.org/10.2217/bmm-2022-0362>
- Wang, Y.-H., Wu, C.-C., Bai, C.-H., Lu, S.-C., Yang, Y.-P., Lin, Y.-Y., *et al.* (2021). Evaluation of the diagnostic accuracy of COVID-19 antigen tests: A systematic review and meta-analysis. *J. Chinese Med. Assoc.* 84.
- Wannamethee, S. G., Lowe, G. D. O., Whincup, P. H., Rumley, A., Walker, M., Lennon,

- L. (2007). Adipokines and risk of type 2 diabetes in older men. *Diabetes Care*, 30(5), 1200–1205. <https://doi.org/10.2337/dc06-1991>
- Wei, L.H., Kuo, M.L., Chen, C.A., Chou, C.H. (2003). Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. *Oncogene*. 22(10):1517-27. <https://doi.org/10.1038/sj.onc.1206226>
- Williams, G.W., Berg, N.K., Reskallah, A., Yuan, X., Eltzschig, H.K. (2021). Acute Respiratory Distress Syndrome. *Anesthesiology*.134(2):270–282.
- Wong, R.S.Y. (2021). Inflammation in COVID-19: from pathogenesis to treatment. *Int. J. Clin. Exp. Pathol.* 14, 831–844.
- Xu, Z., Liu, X., & Zhu, Y. (2021). Serum IL-6 level and its association with liver fibrosis in chronic hepatitis B patients. *Liver International*, 41(1), 136-144. <https://doi.org/10.1111/liv.14612>
- Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Xiao, J., *et al.* (2020). Review article COVID-19: Immunopathogenesis and immunotherapeutics, In Signal transduction and targeted therapy, Volume 5 (128), China: Springer nature, p.1-8
- Yuki, K., Fujiogi, M., Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. *Clin. Immunol.* 215, 108427. <https://doi.org/10.1016/j.clim.2020.108427>
- Zhang, J., Hao, Y., Ou, W. Ming, F., Liang, G., Qian, Y., *et al.* (2020). Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. *J Transl Med.* 18, 406. <https://doi.org/10.1186/s12967-020-02571-x>
- Zhang, W., Wang, W., Yu, H., Zhang, Y., Dai, Y., Ning, C., *et al.* (2012). Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. *Hypertension*, 59(1), 136–144. <https://doi.org/10.1161/HYPERTENSIONAHA.111.173328>
- Zhang, C., Wu, Z., Li, J.W., Zhao, Wang, G.Q. (2020). The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. In *International journal of antimicrobial Agents*, ELSEVIER, 1-6
- Zhang, Y., Wang, L., Li, X. (2023). Elevated serum IL-6 as a negative prognostic biomarker in glioblastoma: Integrating bioinformatics and clinical validation. *Journal of Cancer*, 16(5), 802–810. <https://doi.org/10.7150/jca.75528>
- Zhu, J., Zhong, Z., Ji, P., Li, H., Li, B., Pang, J., *et al.* (2020). Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. *Fam. Med. community Heal.* 8, e000406–e000406. <https://doi.org/10.1136/fmch-2020-000406>

Zhu, X., Gebo, K.A., Abraham, A.G., Habtehyimer, F. (2023). Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study. *Lancet Microbe*. 4(9): e692–e703. [https://doi.org/10.1016/S2666-5247\(23\)00171-4](https://doi.org/10.1016/S2666-5247(23)00171-4).